OncoTherics is delighted to announce the formation of OncoTherics Poland Sp.Zo.o., a wholly owned subsidiary of OncoTherics Limited, formed specifically to pursue the development of our patented asset OCT1002 in prostate cancer.

Stefan Ogrodzinski (CEO OncoTherics) said; “This is a very exciting and important milestone in our company’s strategic development. Poland offers many attractive opportunities for life science companies, especially the emergence of highly talented, young life-science entrepreneurs and the potential for significant European grant funding to stimulate further commercial investment in innovative research and development. We are investing in Poland and we expect very fruitful returns.”